Arthritis

Orthogen seeks to build Europe-wide distribution of Orthokine

Published in Medical Letter on the CDC and FDA, March 19th, 2006

After the successful completion of clinical studies, the German biotech company Orthogen AG (Dusseldorf) intends to build up a Europe-wide distribution of Orthokine, a medical device for the production of autologous conditioned serum containing anti-inflammatory cytokine antagonists and growth factors.

Two universities performed randomized double-blind studies demonstrating its high efficacy and safety in the therapy of osteoarthritis of the knee and low back pain.

After the build up of the Germany-wide sales in the last year, the molecular orthopedics specialist company intends to extend its activities to the E.U. market. U.S. Food & Drug...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2006-03-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry